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ABSTRACT
Carbendazim (methyl 2-benzimidazolecarbamate) and its parent compound benomyl are systemic fungicides that have reproductive and developmental toxicity in male rats. The major objectives of this study were to determine the ability of carbendazim
exposure in utero to alter androgen-dependent development markers in rat offspring and investigate the effects of antiandrogen
flutamide on the carbendazim-mediated reproductive and developmental alterations. Pregnant female rats were treated with 6.25,
12.5 or 25 mg/kg carbendazim, 25, 50 or 100 mg/kg benomyl, and 0.6, 2.5 or 10 mg/kg flutamide by gavage once daily from gestational day 0 to 20. Alternatively, another group of female rats was cotreated with 25 mg/kg carbendazim or 100 mg/kg benomyl
and 0.6, 2.5, and 10 mg/kg flutamide. The various treatments decreased the survival rates of pups on postnatal day (PND) 1 and
21. In male offspring, 12.5 and 25 mg/kg carbendazim increased anogenital distance (AGD), an androgen-dependent marker,
on PND 2. Treatment with benomyl also increased AGD. Cotreatment with 25 mg/kg carbendazim with 0.6, 2.5, and 10 mg/kg
flutamide blocked the androgenic effect on AGD induced by carbendazim. The androgenic effects of carbendazim and benomyl
on AGD were reversible on PND 22 and later. Carbendazim had no effects on other androgen-dependent markers including testis
and epididymis malformations, hypospadias, nipple retention, and organ weights of seminal vesicle and levator ani bulbocavernosus muscle on PND 56. Surprisingly, carbendazim antagonized the antiandrogenic effects on these markers induced by flutamide
cotreatment. In female offspring, carbendazim produced synergistic effects on the flutamide cotreatment-mediated increases of
organs weights in liver and kidney on PND 56. Carbenazim had no marked effects on female reproductive organs. These findings
show that carbendazim exposure in utero displays a transient and weak androgenic effect and reduces flutamide antiandrogenicity
in male rats. The fungicide enhances flutamide-mediated liver and kidney weight increases in female rats. The antagonistic and
synergistic carbendazim and flutamide interactions in utero warrant further investigations.
Key words: carbendazim, benomyl, flutamide, reproductive development, in utero

INTRODUCTION
Ca r b e nd a z i m (met hyl 2- b e n z i m id a z ole ca r bamate) a nd benomyl [met hyl 1- ( but ylca rbamoyl) -2benzimidazolecarbamate] were introduced as commercial
f ungicides in 1972 (Fig u re 1). Benomyl is rapidly
converted to carbendazim in the environment and in
experimental animals. The widely used f ungicides
h a v e r e p r o d u c t i v e a n d d e v e l o p m e n t a l t o x i c i t y.
Administration of carbendazim to male rats induced
sloughing of seminiferous epithelium and severe atrophy
and occlusions of seminiferous t ubule in testis (1-3) .
Carbendazim administration in utero decreased litter size
and induced irreversible infertility, embryonic death, and
growth retardation in rat offspring(4-6). Benomyl caused
reproductive effects such as detachment and sloughing
of germ cells, occlusion of efferent ductules in testis, and
decreases of tissue weight and sperm count in epididymis
*
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of rats(7-9).
Endocrine-disrupting active compounds including
pesticides are potential reproductive and developmental
toxicants (10,11) . For instance, in utero exposu re to
antiandrogens f lutamide (Figure 1), linuron, and p,p’DDE resulted in decrease of anogenital distance (AGD)
and retention of nipples in male rat offspring. These
antiandrogenic activities were associated with permanent
malfor mations of androgen-dependent reproductive
organs such as testis and epididymis (12-14) . Pre- and
post-natal exposure to f lutamide and linuron decreased
seminal vesicle and levator ani bulbocavernsous muscle
weights in male rats (14,15). In utero administration of
androgen testosterone propionate increased AGD at
weaning and adulthood, reduced number of areolas and
nipples, and induced the presence of prostate tissue in
female rats (16). Exposures to antiandrogen vinclozolin
and estrogen methoxychlor promoted an adult testis
phenotype of decreased spermtatogenic capacity and
male infertility in F1 to F4 generations(17). These studies
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Figure 1. Chemical structures of carbendazim, benomyl and flutamide.

indicate that endocrine disruption may play a mechanistic
role in developmental and reproductive toxicity and it is
important to define the endocrine-disrupting activity of a
xenobiotic.
The endocrine-disrupting activity of carbendazim
has not been clearly defined. Treatment of male rats with
carbendazim increased testosterone level and androgen
binding protein concentration in the interstitial and
seminiferous tubule f luid, suggesting an androgenic
activity in vivo (1) . Premating treatment of male and
female rats with carbendazim resulted in androgenic
effects including absence of vagina and presence of
seminal vesicles in female offspring(18). Treatment with
carbendazim and benomyl increased the activity and
mRNA level of aromatase of human ovarian granuloselike tumor cell line KGN, indicating the benzimidazole
fungicides were estrogenic in vitro(19). Carbendazim was
negative for agonistic and antagonistic activity in reporter
gene assays for the human estrogen receptor α and
androgen receptor (20). Direct information regarding the
endocrine-disrupting activity of carbendazim exposure in
utero remains unavailable.
The present study investigated whether exposure
to carbendazim during gestation causes reproductive
effects and induces alterations of androgen-dependent
d e v e l o p m e n t a l m a r k e r s . We h y p o t h e s i z e d t h a t
c a r b e nd a z i m p ro d uc e s a nd roge n ic ef fe c t s on t he
developmental markers, which can be reversed by an
antiandrogen, f lutamide. In these regards, rats were
exposed to carbendazim and f lutamide in utero from
gestation day (GD) 0 to 20 alone and in combination.
Fu r ther more, thei r effects on and rogen- dependent
endpoints were determined in male and female offspring
from postnatal day (PND) 2 to 56. For comparison
purposes, a parallel study was conducted using rats treated
with benomyl.

MATERIALS AND METHODS
I. Animals
Three-week-old male and female Sprague-Dawley
rats were purchased from the National Laboratory Animal

Center, Taipei, Taiwan. Rats were housed in specificpathogen-free animal facility in Taiwan Agricultural
Chemicals and Toxic Substances Research Institute,
Taichung, Taiwan. Animal rooms were maintained under
a 12-hour light and dark cycle, 23 ± 2˚C, and 50 ± 10%
relatively humidity. Animal had access ad libitum to
deionized water and rodent chow (LabDiet ® 5001, PMI
Nutrition International, LLC, Brentwood, MO, USA).
Upon arrival, rats were quarantined for at least one week
and released on the basis of adequate body weight and
free from clinical signs of disease or injury. Male and
female rats were mated within each treatment group for
14 days. GD 0 was defined as the day that sperm was
found in vagina of the mated female. Animal allocation to
treatment groups was done by body weight randomization
to ensure unbiased weight distribution across groups.
I n d i v i d u a l d a m s a n d of f s p r i n g w e r e h o u s e d i n
polycarbonate cages on Laboratory Animal Bedding
(TCP Chipsi Heimtier Steu, Germany) until weaning
PND 21, at which the test subjects were group-housed,
up to 5 per cage, by sex and treatment until necropsy on
PND 56. Male and female offspring were euthanized by
CO2 asphyxiation and subjected to detailed postmortem
examination.
II. Treatment
Carbendazim and benomyl (99% pure) were obtained
from Sinon Co., Taichung, Taiwan. All other chemicals
were obtained from Sigma (St. Louis, MO, USA) unless
otherwise noted. Pesticide or flutamide was suspended in
corn oil and administered to animals orally by gavage in a
volume of 2.5 mL/kg body weight, once daily. From GD
0 to 20, 5 dams per dose were treated with carbendazim at
6.25, 12.5, and 25 mg/kg; benomyl at 25, 50, and 100 mg/
kg; or flutamide at 0.6, 2.5, and 10 mg/kg. Alternatively,
rats were cotreated with 25 mg/kg carbendazim and 0.6,
2.5, and 10 mg/kg flutamide or with 100 mg/kg benomyl
and 0.6, 2.5 or 10 mg/kg flutamide. Dams were examined
daily for clinical signs of toxicity. Dam body weight and
food consumption were monitored daily throughout dosing
and lactation. Rat offspring were weaned at PND 21 and
fed up to 8-week-old. Dam organ weight was determined
on PND 21. The conception rate during GD 21 and 22,
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proportion of pups born alive on PND 1, proportion of
pups surviving to weaning on PND 21, and sex ratio on
PND 56 were calculated.
III. Androgen-dependent Reproductive Development End
Points
The androgen-dependent reproductive end points
included sig ns of clinical toxicit y, AGD, male and
female pup weight, retention of areolae and/or nipples,
malformations of external genitalia, testicular descent,
preputial separation, vaginal opening, and organ weight
and malformation on PND 56(13,21). Pups were counted
and examined for signs of clinical toxicity on PND 0
and were individually identified by tail-labels on PND
21. AGD, and live male and female offspring weights
for all pups were measured on PND 2, 22, and 42. Age
of completion of preputial separation and body weight in
male offspring during PND 40 and 50 were also measured.
Age of onset of vaginal opening and body weight in
female offspring during PND 30 and 45 were determined.
G ross mor pholog y of re product ive orga n s, n ipple
retention, abnormal testis and epididymis, hypospadias,
underdevelopment of prostate or/and seminal vesicle,
absent prostate or/and seminal vesicle, bladder stone, and

underdevelopment of levator ani bulbocavernosus muscle
in male offspring were recorded on PND 56.
IV. Necropsy of Dams
P u p s we r e we a n e d o n P N D 21. D a m s we r e
euthanized by CO 2 asphy xiation. Body and organ
weights, liver, kidneys, adrenals, uterus, ovaries, thyroids
and number of implantation sites were recorded on PND
21.
V. Necropsy of F1 Animals
M a le a n d fe m a le of f s p r i n g o n PN D 56 we r e
euthanized by CO 2 asphyxiation and trunk blood was
collected. Following blood collection, the vent ral
surface of the test subject was shaved for counting the
number of nipples. The external genitalia, including the
scrotum, prepuce, and penis in male offspring and vaginal
in female offspring were visually inspected. Gross
internal examination of the reproductive tract included
inspection of the testes, epididymides, prostate, seminal
vesicles, levator ani bulbocavernosus muscle, and penis.
Additionally, the liver, kidneys, adrenal glands and
thyroids were grossly examined and weighed. Body and

Table 1. Effects of in utero exposures to carbendazim, benomyl, and flutamide on live pups and sex ratio of male and female offspring on
PND 1, PND 21, and PND 56
Treatment

Control
Carbendazim

Benomyl

Flutamide

Carbendazim + Flutamide

Benomyl + Flutamide

Proportion of live
pups on PND 1

Proportion of
survival pups
on PND 21

Sex ratio of live
Live offspring per litter on
offspring on PND
PND 56
56

Dose
(mg/kg)

Number
of litters

Male

Female

6.25

5
5

0.97 ± 0.04
0.82 ± 0.06*

0.97 ± 0.05
0.80 ± 0.05*

5.8 ± 1.6
4.6 ± 1.5

6.8 ± 2.3
5.0 ± 2.9

0.47 ± 0.15
0.48 ± 0.14

12.5

5

0.83 ± 0.05*

0.80 ± 0.04*

5.7 ± 2.3

5.7 ± 1.5

0.49 ± 0.17

25

5

*

0.73 ± 0.06

0.70 ± 0.04*

3.8 ± 3.3

2.5 ± 1.3*

0.49 ± 0.35

25

5

0.80 ± 0.06*

0.79 ± 0.05*

5.6 ± 2.2

5.0 ± 4.3

0.58 ± 0.29

50

4

0.86 ± 0.13*

0.84 ± 0.14*

6.0 ± 0.0

7.0 ± 1.4

0.46 ± 0.05

a

100

5

0.00 ± 0.00

N.A.

0.6

5

0.78 ± 0.04*

0.75 ± 0.06*

7.0 ± 1.7

N.A.

N.A.
5.3 ± 2.3

0.57 ± 0.13

N.A.

2.5

5

0.89 ± 0.04*

0.87 ± 0.05*

6.3 ± 2.9

5.5 ± 2.6

0.54 ± 0.16

10

5

*

0.91 ± 0.03

0.88 ± 0.04*

7.0 ± 1.7

6.0 ± 2.0

0.54 ± 0.11

25 + 0.6

5

0.80 ± 0.05*†

0.79 ± 0.06*†

6.6 ± 3.0

6.0 ± 1.2†‡

0.51 ± 0.14

25 + 2.5

4

0.81 ± 0.05*†

0.79 ± 0.05*†

6.2 ± 2.2

3.8 ± 3.6*

0.70 ± 0.28

25 + 10

4

*‡

0.71 ± 0.05

*‡

0.70 ± 0.06

6.5 ± 2.1

5.0 ± 2.8

0.57 ± 0.22

100 + 0.6

4

0.83 ± 0.10*

0.82 ± 0.08*

6.0 ± 3.9

4.5 ± 3.1

0.66 ± 0.24

100 + 2.5
4
0.90 ± 0.07*
0.88 ± 0.05*
7.0 ± 2.6
5.0 ± 1.2
0.57 ± 0.10
*
100 + 10
5
0.85 ± 0.07
0.84 ± 0.08*
5.6 ± 3.3
3.8 ± 2.7
0.58 ± 0.24
Pregnant Sprague-Dawley rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from GD 0
to 20. Control rats were treated with corn oil only. Pregnant dams were kept to delivery of the offspring at term. Rat offspring were weaned
on PND 21 and fed up to 8 weeks old. Number of live pups per litter and sex ratio at 8-week-old are presented as mean ± SD for number of
litters.
a
N.A.: not available due to embryotoxicity of benomyl.
*
Value is significantly different from the control value, p < 0.05.
†
Value is significantly different from the respective value of treatment with 25 mg/kg carbendazim alone, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.
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organ weights including testes, epididymides, prostate,
seminal vesicles with fluid, levator ani bulbocavernosus
muscle, and penis, liver, kidneys, adrenals and thyroids
were collected. Tissues were f ixed in 10% neut ral
buffered formalin, processed, sectioned, and stained with
hematoxylin and eosin.
VI. Statistical Analysis
All data were expressed as mean ± SD. Data were
subjected to analysis of variance (ANOVA) followed by
Student’s t-test. The level of significance was set at p <
0.05.

RESULTS
Tr e a t m e n t w i t h 6 . 2 5 , 1 2 . 5 , a n d 2 5 m g / k g
carbendazim; 25, 50, and 100 mg/kg benomyl; and 0.6,
2.5, and 10 mg/kg f lutamide from GD 0 to 20 had no
effects on maternal food consumption, body weight,
and implantation site (data not shown). On PND 1,
carbendazim at the doses of 6.25, 12.5, and 25 mg/kg
resulted in 15%, 14%, and 25% decreases of live pups
born, respectively (Table 1). Benomyl at 25, 50, and 100
mg/kg produced 19%, 13%, and 100% decreases in live
pups. Treatment with 0.6, 2.5, and 10 mg/kg flutamide
caused 20%, 8%, and 6% drop, respectively. On PND 21,
carbendazim, benomyl, and flutamide decreased survival
rate, in manners similar to the decreases observed on PND
1. On PND 56, the numbers of live male and female rats
per litter and sex ratio in the variously single treatment
groups were similar to the respective controls with the
exception that 25 mg/kg carbendazim decreased number

of female rats by 63%. On the other hand, cotreatment of
25 mg/kg carbendazim with 0.6 and 2.5 mg/kg flutamide
increased the survival rate by 10% and 11% on PND 1
and by 13% on PND 21, respectively, compared to that of
treatment with 25 mg/kg carbendazim alone. Cotreatment
with carbendazim and f lutamide had no effects on the
numbers of live male rats per litter and sex ratio on PND
56, compared to treatment with carbendzim. Cotreatment
with carbendazim and 0.6 mg/kg f lutamide resulted in
a 140% increase of live female rats per litter, relative to
treatment with carbendazim. Cotreatment with 100 mg/
kg benomyl and f lutamide blocked the embryotoxicity
induced by treatment with benomyl. Carbendazim,
benomyl, and flutamide had no marked effects on maternal
organ weights of ovary, uterus, liver, kidney, adrenal, and
thyroid on PND 21 (data not shown). The later studies
had no results from rats cotreated with benomyl and
f lutamide because no comparisons could be made with
the results from rats treated with benomyl alone due to
embryotoxicity.
Treatment with 6.25, 12.5, and 25 mg/kg carbendazim
produced no effect, 8%, and 4% increases of AGD in male
rats on PND 2, respectively (Table 2). Benomyl at 25 and
50 mg/kg produced 4% and 9% increases. In contrast,
treatment with the antiandrogen flutamide at 0.6, 2.5, and
10 mg/kg caused 4%, 10%, and 16% decreases. On PND
22 and 42, carbendazim and benomyl had no effects on
AGD and f lutamide caused dose-dependent decreases.
Cotreatment with carbendazim and 0.6, 2.5, and 10 mg/kg
flutamide did not produce dose-related changes of AGD,
compared to treatment with carbendazim alone on PND 2.
AGD of rats cotreated with carbendazim and fluamide was
43% to 77% greater than that of rats treated with flutamide
alone on PND 22 and was 7% to 10% greater on PND

Table 2. Effects of in utero exposures to carbendazim, benomyl, and flutamide on AGD of male offspring on PND 2, PND 22, and PND 42
Treatment
Control
Carbendazim

Benomyl
Flutamide

Dose (mg/kg)

PND 2

PND 22

PND 42

6.25

30
23

0.58 ± 0.05
0.58 ± 0.03

1.82 ± 0.13
1.83 ± 0.13

3.91 ± 0.31
4.05 ± 0.31

12.5

17

0.62 ± 0.01*

1.86 ± 0.14

3.87 ± 0.37

25

14

0.60 ± 0.03*

1.91 ± 0.17

3.87 ± 0.26

25

20

0.60 ± 0.03*

1.81 ± 0.15

3.89 ± 0.18

50

12

0.63 ± 0.04*

1.91 ± 0.19

3.92 ± 0.25

0.6

16

0.55 ± 0.05*

1.32 ± 0.15*

3.91 ± 0.40

2.5

25

0.52 ± 0.01*

1.23 ± 0.13*

3.72 ± 0.35*

19

*

*

3.29 ± 0.25*

‡

4.31 ± 0.30‡

10
Carbendazim + Flutamide

AGD (cm)

Number of rats

25 + 0.6

31

0.49 ± 0.03

0.57 ± 0.08

1.10 ± 0.13
2.05 ± 0.37

‡

25 + 2.5
15
0.57 ± 0.03
1.75 ± 0.62
3.98 ± 0.44‡
‡
25 + 10
13
0.53 ± 0.02
1.95 ± 0.70
3.60 ± 0.35‡
Pregnant Sprague-Dawley rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from GD 0
to 20. Control rats were treated with corn oil only. AGD of offspring was measured from PND 2 to 42. Data are presented as mean ± SD for
number of rats.
*
Value is significantly different from the control value, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.
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42. These data indicated that carbendazim reduced the
antiandrogenic effects of flutamide in the cotreated rats.
Treatment with 6.25, 12.5 and 25 mg/kg carbendazim
delayed the age at preputial separation in male rats by 4%,
5%, and 4%, respectively, during PND 40 to 50 (Table
3). Treatment with 25 mg/kg benomyl caused an 8%
delay. Flutamide at 0.6 and 2.5 mg/kg had no effects on
the age of reproductive development. The antiandrogen

at 10 mg / kg caused hy pospadias and consequently
preputial separation was not measured. Cotreatment with
carbendazim and flutamide did not produce dose-related
changes of preputial separation age, relative to that of
treatment with carbendazim alone.
Exposure to 6.25, 12.5, and 25 mg/kg carbendazim
or 25 and 50 mg/kg benomyl had no effects on nipple
retention in male rats on PND 56 (Table 4). Exposure to

Table 3. Effects of in utero exposures to carbendazim, benomyl, and flutamide on sexual development in male offspring PND 40 to 50
Treatment
Control
Carbendazim

Benomyl
Flutamide

Carbendazim + Flutamide

Dose (mg/kg)

Preputial separation

Number of rats

Age of completion (day)

Body weight (g)

6.25

30
23

43.1 ± 1.6
44.7 ± 2.1*

158.1 ± 19.2
190.8 ± 20.3*

12.5

17

45.3 ± 2.2*

165.0 ± 19.1

25
25

14
20

44.9 ± 1.6*
46.6 ± 2.5*

195.4 ± 23.8*
176.9 ± 20.7*

50

12

43.0 ± 1.8

160.4 ± 11.8

0.6

16

43.6 ± 1.2

157.8 ± 21.0

2.5

25

43.7 ± 0.9

164.3 ± 22.0

10

19

N.A.a

25 + 0.6

N.A.
*‡

31

165.6 ± 16.2†‡

45.3 ± 2.3

25 + 2.5
15
44.4 ± 2.1
175.5 ± 16.0*†
*
25 + 10
13
45.0 ± 2.5
179.4 ± 11.7*†
Pregnant Sprague-Dawley rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from GD 0
to 20. Control rats were treated with corn oil only. Age of completion for preputial separation and body weight in male offspring following in
utero exposure to carbendazim, benomyl, and flutamide singly or in combination were measured during PND 40 to 50. Data are presented
as mean ± SD for number of rats.
a
N.A.: not available; male offspring showed hypospadias and preputial separation was not determined.
*
Value is significantly different from the control value, p < 0.05.
†
Value is significantly different from the respective value of treatment with 25 mg/kg carbendazim alone, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.
Table 4. Effects of in utero exposures to carbendazim, benomyl, and flutamide on nipple retention in male offspring on PND 56
Treatment

Incidence of nipple retention

Dose (mg/kg)

Pair of nipple
Control
Carbendazim

Benomyl
Flutamide

Carbendazim + Flutamide

Number of nipples
per pup

0

1

2

3

6.25

30/30 (5/5)a
23/23 (5/5)

0/30 (0/5)
0/23 (0/5)

0/30 (0/5)
0/23 (0/5)

0/30 (0/5)
0/23 (0/5)

0
0

12.5

17/17 (5/5)

0/17 (0/5)

0/17 (0/5)

0/17 (0/5)

0

25

14/14 (5/5)

0/14 (0/5)

0/14 (0/5)

0/14 (0/5)

0

25

20/20 (5/5)

0/20 (0/5)

0/20 (0/5)

0/20 (0/5)

0

50

12/12 (4/4)

0/12 (0/4)

0/12 (0/4)

0/12 (0/4)

0

0.6

16/16 (5/5)

0/16 (0/5)

0/16 (0/5)

0/16 (0/5)

0

2.5

24/25 (5/5)

0/25 (0/5)

0/25 (0/5)

1/25 (1/5)

0.24 ± 1.20

10

2/19 (1/5)

2/19 (1/5)

15/19 (5/5)

0/19 (0/5)

3.37 ± 1.34*

25 + 0.6

31/31 (5/5)

0/31 (0/5)

0/31 (0/5)

0/31 (0/5)

0

25 + 2.5
15/15 (4/4)
0/15 (0/4)
0/15 (0/4)
0/15 (0/4)
0
25 + 10
13/13 (4/4)
0/13 (0/4)
0/13 (0/4)
0/13 (0/4)
0‡
Pregnant Sprague-Dawley rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from GD 0
to 20. Control rats were treated with corn oil only. Nipple retention of male offspring was measured on PND 56. Data are presented as mean
± SD for number of rats.
a
Litter incidence in parenthesis.
*
Value is significantly different from the control value, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.
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10 mg/kg flutamide resulted in a marked increase of nipple
retention, whereas the 0.6 and 2.5 mg/kg exposures had
no effects. Cotreatment with carbendazim and flutamide

blocked the f lutamide-mediated increase of nipple
retention, indicating an antagonistic interaction between
the fungicide and the antiandrogen.

A. Control

B. 10 mg/kg flutamide

C. 25 mg/kg carbendazim

D. 25 mg/kg carbendazim + 10 mg/kg flutamide

Figure 2. Effects of in utero exposures to carbendazim and flutamide on gross morphology of testes and epididymides in male offspring on
PND 56. Pregnant female rats were administered orally with carbendazim and flutamide alone or in combination from GD 0 to 20. Control
rats were treated with corn oil only. Male offspring were sacrificed on PND 56. In comparison with control (A), testis and epididymis of rats
treated with 10 mg/kg flutamide (B) showed inflammation. Histopathology scores of testis and epididymis of rats treated with flutamide were
higher than those of controls, rats treated with carbendazim, and rats cotreated with carbendazim and flutamide (data not shown). The sizes of
testes rats treated with 25 mg/kg carbendazim (C) were smaller than those of controls. Morphology and sizes of testis and epididymis from rats
cotreated with 25 mg/kg carbendazim and 10 mg/kg flutamide (D) were comparable to those of controls.

A. Control

B. 10 mg/kg flutamide

C. 25 mg/kg carbendazim

D. 25 mg/kg carbendazim + 10 mg/kg flutamide

Figure 3. Effects of in utero exposures to carbendazim and flutamide on gross morphology of penis in male offspring on PND 56. SpragueDawley rats were administered orally with carbendazim and flutamide alone or in combination once daily from GD 0 to 20. Control rats
were treated with corn oil only. Male offspring rat were sacrificed on PND 56. Penis of rats treated with 10 mg/kg flutamide (B) showed
hypospadias, in contrast to controls (A). Morphology of penis of rats treated with 25 mg/kg carbendazim (C) was not different from that of
controls. Morphology of penis of rats cotreated with 25 mg/kg carbendazim and 10 mg/kg flutamide and 25 mg/kg carbendazim (D) displayed
a recovery from hypospadias induced by 10 mg/kg flutamide (B).
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The gross examinations of androgen-dependent
organs of male rats on PND 56 showed that exposures
to 6.25, 12.5, and 25 mg/kg carbendazim or 25 and
50 mg/kg benomyl increased formations of abnormal
testis and epididymis and bladder stone. However, the

increases were not statistically significant (Table 5).
The testis and epididymis abnormalities included size
reduction, malformed morphology, and inf lammation
(Figure 2). Exposure to 0.6, 2.5, and 10 mg/kg flutamide
caused increasing incidences of abnormal testis and

Table 5. Effects of exposures to carbendazim, benomyl, and flutamide on gross morphology of reproductive organs of male offspring on
PND 56
Treatment

Incidence of malformationsa

Dose (mg/kg)

Control
Carbendazim

Benomyl
Flutamide

Carbendazim + Flutamide

A

B

D

E

F

G

6.25

0/30 (5/5)b
0/23 (5/5)

0/30 (0/5)
0/23 (0/5)

0/30 (0/5)
0/23 (0/5)

C

0/30 (0/5)
0/23 (0/5)

0/30 (0/5)
0/23 (0/5)

0/30 (0/5)
0/23 (0/5)

0/30 (0/5)
0/23 (0/5)

12.5

2/17 (1/5)

2/17 (1/5)

0/17 (0/5)

0/17 (0/5)

0/17 (0/5)

0/17 (0/5)

0/17 (0/5)

25

1/14 (1/5)

1/14 (1/5)

0/14 (0/5)

0/14 (0/5)

0/14 (0/5)

3/14 (2/5)

0/14 (0/5)

25

0/20 (0/5)

0/20 (0/5)

0/20 (0/5)

0/20 (0/5)

0/20 (0/5)

1/20 (1/5)

0/20 (0/5)

50

1/12 (1/4)

1/12 (1/4)

0/12 (0/4)

0/12 (0/4)

0/12 (0/4)

0/12 (0/4)

0/12 (0/4)

0.6

3/16 (2/5)

3/16 (2/5)

0/16 (0/5)

0/16 (0/5)

0/16 (0/5)

1/16 (1/5)

0/16 (0/5)

2.5

3/25 (2/5)

3/25 (2/5)

7/25 (3/5)*

0/25 (0/5)

0/25 (0/5)

2 /25 (1/5)

0/25 (0/5)

10

7/19 (4/5)*

7/19 (4/5)*

18/19 (5/5)*

1/19 (1/5)

1/19 (1/5)

1/19 (1/5)

0/19 (0/5)

25 + 0.6

5/31 (3/5)

5/31 (3/5)

0/31 (0/5)

0/31 (0/5)

0/31 (0/5)

0/31 (0/5)

0/31 (0/5)

25 + 2.5
1/15 (1/4)
1/15 (1/4)
0/15 (0/4)‡
0/15 (0/4)
0/15 (0/4)
0/15 (0/4)
0/15 (0/4)
‡
‡
25 + 10
0/13 (0/4)
0/13 (0/4) 9/13 (4/4)*‡ 1/13 (1/4)
1/13 (1/4)
2/13 (1/4)
0/13 (0/4)
Pregnant Sprague-Dawley rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from GD 0
to 20. Control rats were treated with corn oil only. Rat offspring were weaned on PND 21 and incidence of abnormal androgen-dependent
tissue was determined on PND 56. Data are presented as mean ± SD for number of rats.
a
Parameters of malformations: A: testis displaying small size, malformed morphology, and inflammation; B: epididymis displaying small
size, malformed morphology, and inflammation; C: hypospadias in penis; D: underdeveloped prostate or/and seminal vesicle; E: absent
prostate or/and seminal vesicle; F: bladder stone; G: underdeveloped levator ani bulbocavernosus muscle.
b
Litter incidence in parenthesis.
*
Value is significantly different from the control value, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05

Table 6. Effects of in utero exposures to carbendazim, benomyl, and flutamide on organ weights in male offspring on PND 56
Treatment
Control
Carbendazim

Benomyl
Flutamide

Carbendazim +
Flutamide

Dose
(mg/kg)

Testis

Epididymis

Kidney

Adrenal

Liver

Na

Body
weight (g)

6.25

30
23

429.2 ± 30.7
432.9 ± 31.6

0.95 ± 0.08
0.93 ± 0.08

0.32 ± 0.03
0.31 ± 0.03

1.12 ± 0.09
1.12 ± 0.08

0.02 ± 0.00
0.02 ± 0.00

5.09 ± 0.49
5.05 ± 0.51

12.5

17

382.5 ± 42.7*

1.00 ± 0.11

0.32 ± 0.04

1.19 ± 0.16

0.02 ± 0.00

4.35 ± 0.63*

25

14

444.5 ± 60.9

0.88 ± 0.18

0.34 ± 0.06

1.11 ± 0.11

0.02 ± 0.00

4.58 ± 0.40*

25

20

431.3 ± 63.8

0.86 ± 0.09*

0.33 ± 0.03

1.05 ± 0.08*

0.02 ± 0.00

4.57 ± 0.59*

*

Organ weight/body weight ratio (g/g × 100)

*

50

12

419.9 ± 33.8

0.86 ± 0.10

0.30 ± 0.05

1.09 ± 0.07

0.01 ± 0.00

4.89 ± 0.32

0.6

16

370.6 ± 31.9*

0.93 ± 0.19

0.35 ± 0.06

1.15 ± 0.08

0.02 ± 0.00

4.77 ± 0.49

2.5

25

377.7 ± 77.6*

0.90 ± 0.19*

0.34 ± 0.05*

1.18 ± 0.13

0.01 ± 0.00*

4.53 ± 0.42*

*

10

19

414.3 ± 46.9

0.81 ± 0.24

0.33 ± 0.04

1.18 ± 0.11

0.02 ± 0.01

4.79 ± 0.30*

25 + 0.6

31

338.9 ± 78.3*†

1.03 ± 0.23*†

0.35 ± 0.09*†

1.15 ± 0.20

0.02 ± 0.01

4.35 ± 0.61*

25 + 2.5
15
387.2 ± 18.3*†
1.02 ± 0.07*‡ 0.33 ± 0.03
1.30 ± 0.09‡
0.02 ± 0.00‡
4.64 ± 0.18*
*†‡
*‡
*†‡
*‡
25 + 10
13
337.0 ± 31.9
1.14 ± 0.28
0.37 ± 0.07
1.36 ± 0.20
0.02 ± 0.01
4.90 ± 0.68
Pregnant Sprague-Dawley rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from GD
0 to 20. Control rats were treated with corn oil only. Offspring were weaned on PND 21 and sacrificed on PND 56. Data are presented as
mean ± SD for number of rats.
a
Number of male offspring examined.
*
Value is significantly different from the control value, p < 0.05.
†
Value is significantly different from the respective value of treatment with 25 mg/kg carbendazim alone, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.
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epididymis, hypospadias (Figure 3), bladder stone, and
underdevelopment and absence of prostate and/or seminal
vesicles. The 10 mg/kg dose group showed 37% increases
of testis and epididymis malfor mations. Exposures
to 2.5 and 10 mg/kg f lutamide increased incidence of
hypospadias by 28% and 95%, respectively. Cotreatment
with carbendazim and 0.6, 2.5, and 10 mg/kg flutamide
had no effects on organ malfor mat ions, compared
to treatment with carbendazim. On the other hand,

cotreatment with carbendazim and 10 mg/kg f lutamide
markedly reduced the incidences of testis and epididymis
malformations and hypospadias induced by f lutamide
(Table 5, Figure 2 and Figure 3).
Treatment with carbendazim, benomyl, and flutamide
did not produce dose-related changes of body weight
or the organ weights of epididymis, adrenal, liver, and
kidney in male rats on PND 56 (Table 6). In testis,
carbendazim had no effects; 25 and 50 mg/kg benomyl

Table 7. Effects of in utero exposures to carbendazim, benomyl, and flutamide on weights of reproductive organs in male offspring on PND
56
Treatment

Dose (mg/kg)

Na

Seminal vesicle Levator ani bulbocavernosus muscle

Prostate

Penis

Organ weight/body weight ratio (g/g × 100)
Control
Carbendazim

Benomyl
Flutamide

Carbendazim + Flutamide

30
23

0.09 ± 0.02
0.09 ± 0.02

0.60 ± 0.08
0.59 ± 0.08

0.42 ± 0.08
0.41 ± 0.08

0.08 ± 0.01
0.08 ± 0.01

12.5

17

0.08 ± 0.02

0.62 ± 0.09

0.44 ± 0.07

0.09 ± 0.01

25

14

0.09 ± 0.02

0.66 ± 0.11

0.38 ± 0.07

0.09 ± 0.01

25

20

0.11 ± 0.03

0.61 ± 0.10

0.39 ± 0.07

0.08 ± 0.02

50

12

0.10 ± 0.02

0.62 ± 0.06

0.42 ± 0.08

0.09 ± 0.01

0.6

16

0.09 ± 0.02

0.67 ± 0.08*

0.45 ± 0.06

0.09 ± 0.01*

6.25

*

2.5

25

0.09 ± 0.03

0.58 ± 0.07

0.38 ± 0.06

0.08 ± 0.01

10

19

0.06 ± 0.02*

0.47 ± 0.16*

0.24 ± 0.09*

0.08 ± 0.02

25 + 0.6

31

0.09 ± 0.04†

0.67 ± 0.17†

0.46 ± 0.09

0.09 ± 0.02†

†

†

‡

25 + 2.5
15
0.08 ± 0.02
0.64 ± 0.11
0.44 ± 0.07
0.09 ± 0.01‡
25 + 10
13
0.07 ± 0.02*†
0.53 ± 0.10†
0.28 ± 0.08*†‡
0.08 ± 0.01†
Pregnant Sprague-Dawley rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from GD 0
to 20. Control rats were treated with corn oil only. Offspring were weaned on PND 21 and sacrificed on PND 56. Data are presented as mean
± SD for male offspring rats.
*
Value is significantly different from the control value, p < 0.05.
†
Value is significantly different from the respective value of treatment with 25 mg/kg carbendazim alone, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.
Table 8. Effects of in utero exposures to carbendazim, benomyl, and flutamide on AGD of female offspring on PND 2, PND 22, and PND
42
Treatment

Dose (mg/kg)

AGD (cm)

Number of rats
PND 2

Control
Carbendazim

Benomyl
Flutamide

Carbendazim + Flutamide

PND 22

PND 42

6.25

31
12

0.42 ± 0.06
0.43 ± 0.05

1.26 ± 0.01
1.02 ± 0.01

2.12 ± 0.01
1.83 ± 0.14

12.5

12

0.43 ± 0.06

0.94 ± 0.01

1.72 ± 0.15*

25

12

0.45 ± 0.08

0.95 ± 0.01

1.88 ± 0.08

25

21

0.42 ± 0.04

0.99 ± 0.01

1.71 ± 0.14*

50

4

0.43 ± 0.08

0.88 ± 0.01

1.81 ± 0.08

0.6

14

0.37 ± 0.06*

0.95 ± 0.03*

1.85 ± 0.13

2.5

20

0.32 ± 0.05*

0.87 ± 0.01*

1.73 ± 0.14*

10

18

*

0.30 ± 0.05

*

0.81 ± 0.01

1.73 ± 0.11*

25 + 0.6

18

0.41 ± 0.08

1.06 ± 0.10*

*†

*

2.44 ± 0.20*†‡

25 + 2.5
11
0.31 ± 0.01
0.94 ± 0.12
2.07 ± 0.33‡
*†‡
*
25 + 10
10
0.38 ± 0.08
1.12 ± 0.09
2.07 ± 0.33‡
Pregnant Sprague-Dawley female rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from
GD 0 to 20. Control rats were treated with corn oil only. AGD of female offspring was measured from PND 2 to 42. Data are presented as
mean ± SD for number of rats.
*
Value is significantly different from the control value, p < 0.05.
†
Value is significantly different from the respective value of treatment with 25 mg/kg carbendazim alone, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.

128
Journal of Food and Drug Analysis, Vol. 14, No. 2, 2006
Table 9. Effects of in utero exposures to carbendazim, benomyl, and flutamide on sexual development in female offspring during PND 30
and 45
Treatment
Control
Carbendazim

Benomyl
Flutamide

Carbendazim + Flutamide

Dose (mg/kg)

Vaginal opening

Number of rats

Age of onset (day)

Body weight (g)

6.25

31
12

37.2 ± 2.2
35.2 ± 1.7*

110.8 ± 26.5
107.0 ± 11.6

12.5

12

37.6 ± 4.8

108.0 ± 9.9
*

25

12

34.2 ± 1.5

115.8 ± 7.7

25

21

35.9 ± 2.4

99.4 ± 12.2*

*

50

4

34.0 ± 1.1

108.9 ± 5.6

0.6

14

33.9 ± 1.8*

99.0 ± 9.5*

2.5

20

*

35.0 ± 3.6

97.8 ± 8.1*

10
25 + 0.6

18
18

36.6 ± 2.8
35.7 ± 2.4‡

91.0 ± 25.7*
104.8 ± 12.6†

25 + 2.5
11
36.2 ± 2.5†
107.8 ± 12.4‡
*
25 + 10
10
34.8 ± 1.2
114.7 ± 6.7‡
Age and body weight of onset for vaginal opening in the female offspring following in utero exposure to carbendazim, benomyl, and
flutamide at the designated doses once daily from GD 0 to GD 20 were measured from PND 30 to PND 40. Data are presented as mean ±
SD for number of rats.
*
Value is significantly different from the control value, p < 0.05.
†
Value is significantly different from the respective value of treatment with 25 mg/kg carbendazim alone, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.

caused 10% and 9% decreases; and 0.6, 2.5, and 10 mg/kg
flutamide resulted in no effect, 5%, and 14% decreases of
organ weight, respectively. Cotreatment with 25 mg/kg
carbendazim and 0.6, 2.5, or 10 mg/kg flutamide produced
8%, 7%, and 21% increases, respectively, relative to
controls. The 0.6 mg/kg flutamide cotreatment increased
testis weight by 16%, compared to that of carbendazim
t reat ment alone. The 2.5 and 10 mg / kg f lutamide
cotreatment produced 22% and 41% increases, compared
to those of the respective flutamide treatment alone. In
epididymis, cotreatment with carbendazim and 10 mg/kg
flutamide resulted in 16%, 9%, and 12% increases of tissue
weight relative to controls, carbendazim, and f lutamide
treatment, respectively. In kidney, the 10 mg/kg flutamide
cotreatment resulted in 21%, 23%, and 15% increases in
organ weight, respectively.
Carbendazim and benomyl treatment did not have
dose-dependent effects on organ weights of prostate,
seminal vesicle, levator ani bulbocavernosus, and penis
in male rats (Table 7). Treatment with 2.5 and 10 mg/kg
flutamide decreased levator ani bulbocavernosus muscle
weight by 10% and 44%, respectively. The f lutamide
treatment had no dose-related effects on the other organ
weights. Cotreatment with 25 mg/kg carbendazim and 2.5
or 10 mg/kg flutamide produced 16% and 12% increases
of levator ani bulbocavernosus muscle weight, relative to
those of the respective flutamide treatment.
Exposures to 6.25, 12.5, and 25 mg/kg carbendazim
or 25 and 50 mg/kg benomyl did not produce marked
effects on AGD in female rats on PND 2, 22, and 42
(Table 8). Exposures to 0.6, 2.5 and 10 mg/kg flutamide
decreased the reproductive development marker by 12%,
24%, and 30% on PND 2 and 24%, 31%, and 35% on

PND 22, respectively. Exposures to 2.5 and 10 mg/kg
f lutamide caused 18% decreases of AGD on PND 42.
Coexposures to carbendazim and 0.6, 2.5, and 10 mg/
kg f lutamide resulted in 30%, 10%, and 10% increases
of AGD, compared to carbendazim exposure on PND
42, respectively. The respective coexposures produced
32%, 19%, and 20% increases of AGD, compared to
flutamide exposure alone. Treatment with carbendazim,
benomyl, and f lutamide in utero did not produce doserelated changes of the age at vaginal opening during
PND 30 and 45 (Table 9). Cotreatment with carbendazim
and flutamide did not produce significant changes of the
female reproductive development marker.
Treatment with carbendazim, benomyl, and flutamide
did not alter the body weights of female rats on PND 56
(Table 10). Carbendazim had no marked or dose-related
effects on the organ weights of ovary, uterus, adrenal,
kidney, and liver. In contrast, treatment with 25 and 50
mg/kg benomyl increased ovary weight by 17% and 35%
and kidney weight by 39% and 35%, respectively. The 25
mg/kg benomyl treatment increased liver weight by 14%.
Treatment with benomyl and f lutamide had no effects
on uterus or adrenal weights. Flutamide at 0.6 and 2.5
mg/kg produced 35% and 22% increases of ovary weight,
respectively. In liver, treatment with 0.6, 2.5, and 10
mg/kg flutamide produced 12%, 22%, and 25% increases
of tissue weight, respectively. In kidney, treatment with
2.5 and 10 mg/kg flutamide led to 35% increases of organ
weight, while the 0.6 mg/kg treatment had no effects.
Cotreatment with carbendazim and 0.6, 2.5, and 10 mg/kg
f lutamide resulted in 54%, 54%, and 57% increases of
liver weight, compared to controls; 58%, 57%, and 61%
increases, relative to treatment with carbendazim; and
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Table 10. Effects of in utero exposures to carbendazim, benomyl, and flutamide on weights of reproductive organs in female offspring on
PND 56
Treatment
Control
Carbendazim

Benomyl
Flutamide

Carbendazim +
Flutamide

Dose
(mg/kg)

Ovary

Uterus

Kidney

Adrenal

Liver

Na

Body
weight (g)

6.25

31
12

253.4 ± 39.6
256.4 ± 39.1

0.06 ± 0.02
0.06 ± 0.02

0.31 ± 0.16
0.30 ± 0.16

0.87 ± 0.13
0.85 ± 0.12

0.03 ± 0.01
0.03 ± 0.01

3.84 ± 0.53
3.79 ± 0.52

12.5

12

257.1 ± 37.2

0.06 ± 0.02

0.32 ± 0.16

0.85 ± 0.12

0.03 ± 0.01

3.77 ± 0.48

25

12

258.3 ± 34.0

0.06 ± 0.01

0.35 ± 0.16

0.84 ± 0.11

0.03 ± 0.01

3.75 ± 0.48

25

21

239.2 ± 20.7

0.07 ± 0.01*

0.29 ± 0.10

1.20 ± 0.15*

0.03 ± 0.01

4.37 ± 0.54*

*

*

Organ weight/Body weight ratio (g/g × 100)

50

4

239.4 ± 3.7

0.08 ± 0.00

0.41 ± 0.12

1.17 ± 0.10

0.03 ± 0.01

4.23 ± 0.40

0.6

14

236.2 ± 26.3

0.08 ± 0.01*

0.31 ± 0.19

0.89 ± 0.07

0.03 ± 0.00

4.28 ± 0.51*

*

*

2.5

20

248.9 ± 31.6

0.07 ± 0.01

0.25 ± 0.07

1.17 ± 0.13

0.03 ± 0.00

4.67 ± 0.33*

10

18

242.8 ± 19.3

0.06 ± 0.01

0.31 ± 0.10

1.17 ± 0.11*

0.04± 0.01

4.78 ± 0.56*

25 + 0.6

18

224.8± 15.3†

0.08 ± 0.02*†

0.28 ± 0.11†

1.29 ± 0.14*‡

0.04 ± 0.01‡

5.92 ± 0.50*†‡

25 + 2.5
11
238.7 ± 12.9
0.08 ± 0.01*†‡ 0.36 ± 0.18*†‡ 1.36 ± 0.07*†‡
0.03 ± 0.01‡
5.90 ± 0.44*†‡
‡
*‡
*†‡
‡
25 + 10
10
234.2 ± 35.7
0.06 ± 0.01
0.23 ± 0.07
1.32 ± 0.15
0.03 ± 0.01
6.02 ± 0.99*†‡
Pregnant Sprague-Dawley rats were treated orally with carbendazim, benomyl, and flutamide at the designated doses once daily from GD 0 to
20. Control rats were treated with corn oil only. Female offspring were weaned on PND 21 and sacrificed on PND 56. Data are presented as
mean ± SD for number of rats.
a
Number of female offspring.
*
Value is significantly different from the control value, p < 0.05.
†
Value is significantly different from the respective value of treatment with 25 mg/kg carbendazim alone, p < 0.05.
‡
Value is significantly different from the respective value of treatment with flutamide alone, p < 0.05.

38%, 26%, and 26% increases, compared to the respective
flutamide treatment. Cotreatment with carbendazim and
0.6, 2.5, and 10 mg/kg flutamide resulted in 49%, 57%,
and 52% increases, relative to controls and 45%, 16%,
and 13% increases, compared to the respective flutamide
treatment. The 2.5 and 10 mg/kg flutamide cotreatment
resulted in 61% and 56% increases of kidney weight,
relative to treatment with carbendazim. These liver and
kidney increases indicated synergistic carbendazim and
flutamide interactions.

DISCUSSION
T h e p r e s e n t f i n d i n g s s h ow t h a t e x p o s u r e t o
carbendazim in utero decreases the viability of offspring
and displays androgenic activity in male rats during
weaning. The endocrine-disrupting activity is supported
by the following lines of evidence. Firstly, carbendazim
increased AGD, an androgen-dependent development
end point on PND 2. Secondly, the parent compound of
carbendazim, benomyl, also increased AGD. Thirdly,
the increase was sensitive to the blocking effect of an
antiandrogen flutamide. The endocrine-disrupting activity
of carbendazim is transient and weak because the increase
in male AGD was reversible on PND 22 and 42. In
addition, the fungicide had no effects on other androgendependent end points determined including preputial
separation, nipple retention, and reproductive organ
malformation. In female rats, carbendazim exposure in
utero did not produce marked changes of vaginal opening,

AGD, and female reproductive organ weights.
In utero exposure to benomyl at 100 mg/kg resulted
in embryotoxicity which was blocked by co-exposures
to androgen receptor antagonist flutamide at 0.6, 2.5, and
10 mg/kg. It seems unlikely that the benomyl-induced
reproductive effect was entirely caused by chemical
toxicity, because benzimidazole fungicides are generally
rega rded to have low acute a nd system ic toxicit y.
For instances, LD 50 (orally in rats) of benomyl and
carbendazim are 10 g/kg and 2-15 g/kg, respectively (22,
23)
. The highest doses of benomyl and carbendazim used
in the present studies were 1% and 1.6% to 12.5% of their
respective LD50. The flutamide doses used in the present
study were lower than those used in previous studies of
endocrine-disrupting activities of the antiandrogen(14,30).
Therefore, a direct chemical interaction between benomyl
and flutamide was probably not a mechanism underlying
the blocking effect of flutamide on benomyl embrotoxicity.
On the other hand, an androgen receptor-mediated activity
may play a significant mechanistic role, because coexposure to androgen receptor antagonist produced the
blocking effect. Alternatively, the effect might be a result
of other unidentified activities. For example, Kangasniemi
et al.(24) reported that cotreatment with flutamide and a
gonadotropin-releasing hormone antagonist (Nal-Glu)
suppressed rat spermatogenesis to protect spermatogonial
stem cells against the anticancer drug procarbazine,
possibly as a consequence of altered paracrine regulation.
It remains to be investigated whether hormonal regulation
or other mechanisms are responsible for the blocking of
benomyl embryotoxicity by flutamide.
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The carbendazim-induced alteration in male AGD
is in marked cont rast to the alterations induced by
antiandrogens. Administrations of f lutamide, linuron,
vinclozolin, and procymidone to female pregnant rats
during gestation resulted in decreases of AGD in male rats
on postnatal days (14,25-27). The effects of carbendazim
on reproductive development are different from those of
testosterone propionate, an androgen receptor agonist.
Subcut a neou s exposu re to 0.5 mg of t estosterone
propionate on GD 13-18 produced a transient decrease
in male AGD on PND 2. Exposure to 0.5, 1, 2, and 10
mg of testosterone propionate decreased glands penis
weight of male rats on PND 161-178. In female rats, 0.5
mg of testosterone propionate increased AGD at weaning
and adulthood, reduced number of areolas and nipples,
and removed prostate tissue in adulthood (16) . These
results indicate that the reproductive development effects
of carbendazim are distinct from those of prototypic
antiandrogen and androgen in several aspects. It is
difficult to generalize or predict the endocrine-disrupting
activity of the benzimidazole fungicide.
In the present study, although the flutamide treatment
by gavage on GD 0 to 21 decreased AGD and levator
ani bulbocavernosus muscle weight, it increased nipple
retention, testis and epididymis malfor mations, and
hypospadias in male rats. These f lutamide-induced
alterations of androgen-dependent end points are similar
to the results of McIntyre et al.(14) and Goto et al.(28) in
which flutamide was administered orally at 6.25 to 50 mg/
kg on GD 12 to 21 and subcutaneously at 3 to 30 mg/kg on
GD 16 to 21, respectively.
A major and unexpected finding of this study is that
carbendazim co-administration in utero can protect male
rat offspring against the adverse effects of flutamide on
reproductive development. This conclusion is based on
the results showing that carbendazim diminished the
flutamide-induced AGD reduction, nipple retention, testis
inf lammation, and hypospadias in male offspring. To
the best of our knowledge, this study is the first to show
that a xenobiotic can modulate f lutamide reproductive
development toxicity. The exact mechanisms underlying
this compensatory effect are not clear. Flutamide is
a potent and rogen receptor ant agonist. Treat ment
of male rats with carbendazim increased and rogen
binding protein concentration and activity in testis (1,
18)
. Additions of carbendazim to testis tissue extract
replaced [3H]hydroxytestosterone previously bound to
the androgen receptor (18). These studies suggest that
the androgen receptor may possibly be a common target
of action of f lutamide and carbendazim. Therefore, an
androgen receptor-mediated mechanism may contribute
at least partly to the protective effect of carbendazim in
which fungicide competes with f lutamide for binding
to androgen receptor to diminish the adverse effects of
flutamide on androgen-dependent tissues.
The present study does not exclude the possibility
that the carbendazim protective effect is a manifestation of

the fungicide interacting with flutamide antagonistically
via androgen-receptor independent mechanisms which
are impor tant in reproductive development such as
hypothalamic-pituitary function; biosynthesis, transport,
and metabolism of androgens; and DNA methylation
of critical genes (17,21). Alternatively, carbendazim may
interact with cellular signaling pathway to modulate the
endocrine-disrupting activity of flutamide. For instance,
exposure in utero to the antiandrogen f lutamide at 0.4,
2, or 10 mg/kg altered the expression of genes involved
in t umor g row th factor-β sig naling pathway which
increased apoptotic germ cell death and consequently
hypospermatogenesis in rat testis(29). Carbendazim might
possibly modulate the tumor growth factor-β signaling
pathway or other pathways in a compensatory fashion
to produce the protective effect in testis and related
androgen-dependent tissues. Additional studies are
required to further investigate this and other possibilities.
The present study fur ther showed that in utero
carbendazim co-administration synergistically increased
f lutamide-mediated increases of liver and kidney in
female rats. The mechanisms underlying the synergistic
interaction are not clear. Histological studies of these
tissues did not show marked hepatic or renal lesions
(data not shown). Oral administration of 5 to 100 mg/
kg f lutamide to male rats for 15 days increased liver
weight in a dose-dependent manner (30). Yamaha et al.(20)
reported that oral administration of 300 mg/kg benomyl to
immature female rats for 3 days and castrated male rats for
10 days increased their relative liver weights. Information
on carbendazim-mediated increase of liver or kidney
weight apparently is not available. However, Jacobsen et
al.(31) reported that oral treatment with a mixture of five
pesticides containing carbendazim for 28 days increased
liver weight in male rats. These previous studies indicated
that liver is a target organ of f lutamide, benomyl, and
possibly carbendazim. An increase of liver or kidney
weight can be a reflection of induction of hypertrophy of
the target organs for xenobiotic metabolism. It will be of
interest to determine the in utero effects of carbendazim
and benomyl on liver and kidney xenobiotic-metabolizing
enzymes in rat offspring.
Given carbendazim and benomyl are widely used
agricultural fungicides, the results of the present study
are signif icant to toxicology and valuable to hazard
identif ication, which will facilitate the health r isk
assessment of human exposures to these fungicides.
In conclusion, this repor t shows that carbendazim
exposure in utero induces a minor reproductive toxicity
and a transient androgenic activity in rat offspring.
Carbendazim protects male rats against developmental
toxicity of flutamide and enhances the increases of liver
and kidney weights mediated by the antiandrogen in
female rats. Additional studies are warrant to investigate
the antagonistic and synergistic interactions in utero.
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